Skip to content
BIO is expanding its work to defend IP
When a biotech firm sells investors on the promise of a new drug, what they are really selling is the intellectual property behind their […]
BIO is expanding its work to defend IP Read More »
International
BIO expert: Future of biotech depends on competing with China, updating FDA
Ensuring a brighter future for U.S. biotech requires modernizing the Food and Drug Administration (FDA) and addressing challenges from China, according to Kelly Seagraves,
BIO expert: Future of biotech depends on competing with China, updating FDA Read More »
BIO’s comments for USTR report highlight global threats to intellectual property
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
BIG Summit: Seeking opportunities while navigating risks of global trade
China is becoming an increasingly influential player in the global biotech market. More than a third of U.S. licensing deals this year have involved
BIG Summit: Seeking opportunities while navigating risks of global trade Read More »
BIO 2025: The world can’t wait – it needs to collaborate
Biotech is a global business, and we’re better for it, said experts at the 2025 Biotechnology Innovation Organization (BIO) International Convention in Boston. International
BIO 2025: The world can’t wait – it needs to collaborate Read More »
BIO group to suggest global guidelines for regulating cell and gene therapies
A group led by the Biotechnology Innovation Organization (BIO) will recommend new international guidelines for manufacturers of cell and gene therapies (CGT) to support
BIO group to suggest global guidelines for regulating cell and gene therapies Read More »
BIO IP expert reviews the current policy landscape
Given the importance of intellectual property for biotech, the Biotechnology Innovation Organization (BIO) remains vigilant in ensuring IP is protected. In recognition of World
BIO IP expert reviews the current policy landscape Read More »
BIO’s mission to Tokyo builds on fruitful cooperation
The BIO Delegation (pictured from left): Tasuku Kitada (Strand Therapeutics), Adam Roach (BeOne Medicines, formerly Beigene), Jacob Becraft (Strand Therapeutics), John F. Crowley (BIO),
BIO’s mission to Tokyo builds on fruitful cooperation Read More »
Nobel and World Food Prize holders: Enable biotech innovation for food
The world needs regulatory reform and greater R&D investment to enable “moonshot” biotech innovations in food production that can meet our growing food needs,
Nobel and World Food Prize holders: Enable biotech innovation for food Read More »
USMCA dispute panel halts Mexico’s ban on biotech corn
A dispute panel ruled that Mexico’s planned ban on imports of biotech corn is “not based on relevant scientific principles” and would violate the U.S.-Mexico-Canada
USMCA dispute panel halts Mexico’s ban on biotech corn Read More »